Improving antibody affinity by mimicking somatic hypermutation in vitro. - Wikidata - awgldk - TriplyDB

Improving antibody affinity by mimicking somatic hypermutation in vitro.

Improving antibody affinity by mimicking somatic hypermutation in vitro.

http://www.wikidata.org/entity/Q30724948

about

Mesothelin targeted cancer immunotherapy The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin Recognition of Mesothelin by the Therapeutic Antibody MORAb-009: STRUCTURAL AND MECHANISTIC INSIGHTS In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.By-passing selection: direct screening for antibody-antigen interactions using protein arrays Single-chain variable fragment antibodies against the neural adhesion molecule CHL1 (close homolog of L1) enhance neurite outgrowth.Fine tuning of the specificity of an anti-progesterone antibody by first and second sphere residue engineering.Rapid generation of specific antibodies by enhanced homologous recombination.A general method for greatly improving the affinity of antibodies by using combinatorial libraries Construction and characterization of recombinant single-chain variable fragment antibodies against Toxoplasma gondii MIC2 protein.Isolation of anti-CD22 Fv with high affinity by Fv display on human cells.An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 Design of synthetic antibody libraries.Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway Overview on concepts and applications of Fab antibody fragments.In vitro antibody affinity maturation targeting germline hotspots A novel high-affinity human monoclonal antibody to mesothelin.Development of a novel mammalian cell surface antibody display platform Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.Discovery of mesothelin and exploiting it as a target for immunotherapy.Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.Human anti-EGFL7 recombinant full-length antibodies selected from a mammalian cell-based antibody display library.Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties.Investigational approaches for mesothelioma.Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor.In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing Technologies In vitro affinity maturation and characterization of anti-P24 antibody for HIV diagnostic assay.Mesothelin-targeted agents in clinical trials and in preclinical development.Directed evolution of human scFvs in DT40 cells.Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells

P2860

Q24656242-38C851B4-2FAD-45BD-A49D-1D928092539D Q26771289-8213C0CA-F77F-48AB-9F9E-8EA410327ECD Q27015134-E235F469-3DD5-423A-AE0F-0FAFBE585A59 Q27670713-1600BD31-0D08-49D7-BAF5-56C9F3A09A47 Q30769483-A1566558-58B8-4778-B02E-AE687A5D748A Q30887325-58941AFE-90B9-4065-8129-8841D12A7F9F Q31108009-F8A6B8F6-A142-49BE-BC35-FF3CA306892F Q31170923-8A676C18-6DDC-4B1E-A835-98599DCD0E22 Q33216046-65C66868-8B8F-4A41-A25C-7E2964CF9076 Q33216580-EBAA5B62-D4B3-46E9-B23A-2C6D04E98E40 Q33228870-39250B91-11E5-4AC6-9828-13FFF9D473D6 Q33246226-B6A5AAD8-0CDF-4221-97A8-14693438CCA8 Q33272711-8EE7E757-A920-4BAE-90B7-481B5E40438F Q33283622-E02E920A-D5E0-41F8-89C9-4F73257E2FA2 Q33363266-2F56D19B-B9DB-44B4-9490-B6612A54B38F Q33383237-57DF749F-A18D-4C09-A0C5-5E23DCED912C Q33411367-51F3B787-F39C-41D3-82E6-F9C0DAECAC7A Q33413796-857AA76E-2C04-44F1-8130-3ED9C1973296 Q33634221-5F50C76E-2594-4052-8C4B-1A13A47FDB72 Q33661339-C16F5F71-EACC-4B74-9F6E-074F2C23508B Q33687487-4E354CB8-D882-4E1F-9F26-7D55325B2C91 Q33767727-208F3C27-89B0-4A4B-823B-EBC3C7C316FF Q33772688-BAB9688C-3F62-4B6D-9C98-5AC6C6156199 Q33816551-9A3799C8-B103-4BD6-99CC-9640F5D82902 Q33841251-6E50B540-1781-4FDB-A648-B8BDC44D85C3 Q34035564-4EF79162-E5F4-40DB-993E-05612625DD00 Q34148591-34711942-EB5F-44BA-ADB5-27E8EB4719D3 Q34216604-72CA5499-C977-4BA7-A524-46B2F68CEA15 Q34293068-EE92357B-4ECD-4B6A-8864-4E3C4572E45F Q34313298-D7D10DEA-0517-4918-81A3-BC41C7E4E73C Q34736631-53AB21C4-F23B-4C61-8411-CFA2E5B1ACBF Q34771909-82E46701-F389-4737-AD88-1C0901863F8D Q35049589-7A782D0E-2377-406F-AF5A-EE0EBBA01A4D Q35578041-F8EC4971-24EE-4450-8260-E567F510B46B Q35654123-56F412A4-3717-4F07-8B8C-2D842E670051 Q35688643-377A336C-35CC-4FB2-A913-A247427075CD Q35815380-A579C784-8762-45CA-ADDF-2F488E91EC55 Q35828141-AF0D75F9-2370-44D1-9C79-F931CBA661C3 Q35864980-9DB58B08-814B-44A0-AB30-8177AF1B3DB7 Q35961264-AA7FD20D-4AEF-4632-B5E6-F33CA639ED67

P2860

Improving antibody affinity by mimicking somatic hypermutation in vitro.

http://www.wikidata.org/entity/Q30724948

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Improving antibody affinity by mimicking somatic hypermutation in vitro.

@ast

Improving antibody affinity by mimicking somatic hypermutation in vitro.

@en

type

label

Improving antibody affinity by mimicking somatic hypermutation in vitro.

@ast

Improving antibody affinity by mimicking somatic hypermutation in vitro.

@en

prefLabel

Improving antibody affinity by mimicking somatic hypermutation in vitro.

@ast

Improving antibody affinity by mimicking somatic hypermutation in vitro.

@en

P1433

Q30724948-66484737-7FA0-4A24-A88D-7EF9AECF6E54

P1476

Q30724948-A4E528B8-E74C-42DF-AEC2-5FA8B9238923

P2093

Q30724948-814700C3-6361-4740-BCFC-25882C87819F

Q30724948-C90686B7-71CB-468D-8612-9B2D6A793369

P2860

Q30724948-0E2F2736-60EF-4759-AF35-FBBFC6BA8AD9

Q30724948-10A4169C-B61D-46F5-B905-5C42BA13A627

Q30724948-16FBB53E-52BD-45CD-9C06-C4C50964D7D1

Q30724948-19AA2350-650D-4186-BFE4-04CAB6280443

Q30724948-1D5378F9-487A-4BB4-8C4F-EAA136D715E1

Q30724948-24A68FCE-DA69-48CE-8F15-8634E409D6D9

Q30724948-2B3FD5E2-77FE-457F-B3DC-FDA9DBBA7F71

Q30724948-4DC6D64B-D478-40DB-9EE2-E547A907AFCE

Q30724948-4E6A79D4-4B29-4708-B3CB-A85584BB3E01

Q30724948-6199E16C-0D3A-4ECC-9525-D3B8BD6779E4

P2888

Q30724948-AE579EF4-FD91-4B23-9A97-22945771EB54

P304

Q30724948-131256D5-27CB-4C5B-A451-2F2826E051BF

P31

Q30724948-28793EA9-D810-4174-98C0-6416025D53D1

P356

Q30724948-AB50CE47-804F-4BAC-8D9C-0A56B5779EA5

P433

Q30724948-7C10BBD6-B090-4A23-833C-91496A5CFBFA

P478

Q30724948-1EC6A502-34F9-475A-BACC-1D8826EEC173

P577

Q30724948-A5429474-B3B3-4BFD-A944-87A5C033A27B

P5875

Q30724948-A89AE080-325E-427A-8370-98F4CDF2897D

P698

Q30724948-85930F05-D4DF-4DB0-BC56-9190A572F134

P921

Q30724948-3EDF4852-E212-4EFF-9315-6E284FFBF33D

P356

P1433

Nature Biotechnology

P1476

Improving antibody affinity by mimicking somatic hypermutation in vitro.

@en

P2093

Chowdhury PS

http://www.w3.org/2001/XMLSchema#string

Pastan I

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

Rapid and efficient site-specific mutagenesis without phenotypic selection

In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.

Modifying the sequence of an immunoglobulin V-gene alters the resulting pattern of hypermutation.

Somatic mutation of immunoglobulin lambda chains: a segment of the major intron hypermutates as much as the complementarity-determining regions.

P2888

P304

568-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/9872

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

1999-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12914524

http://www.w3.org/2001/XMLSchema#string

P698

10385321

http://www.w3.org/2001/XMLSchema#string

P921